San Francisco

Frédéric Guerard has been appointed CEO of Graybug Vision. Guerard joins the Redwood City, CA-based eye diseases drug developer from Novartis (NYSE: NVS), where he had several roles, most recently worldwide business franchise head of ophthalmology. Graybug’s lead drug candidate, GB-102, is being prepared for Phase 2 studies testing it as a treatment for the “wet” form of age-related macular degeneration.

Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com Follow @frankvinluan

Trending on Xconomy

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *